Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France
- 10 May 2016
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (8) , 1307-1313
Abstract
Multiple myeloma (MM) is one of the most common hematological malignancies, with an estimated 4888 incident cases in France in 2012. The management of patients with MM has changed considerably in recent years. We proposed an approach to predict the number of patients with multiple myeloma eligible for second- and third-line treatment for the period 2012–2020. The input parameters of this model were incident cases of multiple myeloma from the Basse-Normandie French Regional Registry of Hematological Malignancies (RRHMBN) for the period 2000–2012 and survival rates among patients under and over age 65 from the French National Institute of Statistics and Economic Studies (INSEE). In addition, data on mortality rates and progression-free survival (PFS) were extracted from the literature. Our analyses showed that the total incidence of MM in France is predicted to increase by 29 % between 2012 and 2020. We used the proposed approach to predict that at least 47.8 % of first-line MM patients will be eligible for second-line treatment (and 45.6 % will be eligible for third-line treatment). Predicting the number of patients with MM eligible for a new treatment is a prerequisite to planning healthcare and calculating treatment costs.Keywords
This publication has 22 references indexed in Scilit:
- Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial DataOncology Research and Treatment, 2015
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- International Myeloma Working Group recommendations for global myeloma careLeukemia, 2013
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Unbiased estimates of long‐term net survival of hematological malignancy patients detailed by major subtypes in FranceInternational Journal of Cancer, 2012
- Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myelomaLeukemia, 2011
- On Estimation in Relative SurvivalBiometrics, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisLeukemia, 2011
- Survival of cancer patients in France: A population-based study from The Association of the French Cancer Registries (FRANCIM)European Journal of Cancer, 2007